Shares of Omnicell, Inc. (NASDAQ:OMCL) were up 5.3% on Tuesday . The stock traded as high as $76.00 and last traded at $75.65, approximately 285,700 shares traded hands during mid-day trading. A decline of 13% from the average daily volume of 330,188 shares. The stock had previously closed at $71.85.
Several research analysts have recently weighed in on OMCL shares. Sidoti set a $82.00 target price on shares of Omnicell and gave the company a “hold” rating in a research note on Friday, October 25th. ValuEngine downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Wednesday, September 4th. BidaskClub downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Friday. Zacks Investment Research upgraded shares of Omnicell from a “hold” rating to a “buy” rating and set a $79.00 target price for the company in a research note on Monday, July 29th. Finally, Craig Hallum upgraded shares of Omnicell from a “hold” rating to a “buy” rating and set a $85.00 target price for the company in a research note on Friday, July 26th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $82.75.
The stock has a market capitalization of $3.14 billion, a price-to-earnings ratio of 49.44, a PEG ratio of 2.87 and a beta of 1.08. The firm’s fifty day moving average is $73.50 and its 200-day moving average is $76.21. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.09 and a quick ratio of 1.63.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, October 24th. The company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.05. The firm had revenue of $228.80 million for the quarter, compared to analysts’ expectations of $231.86 million. Omnicell had a net margin of 6.28% and a return on equity of 11.90%. The firm’s quarterly revenue was up 12.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.63 earnings per share. On average, sell-side analysts expect that Omnicell, Inc. will post 2.09 EPS for the current year.
In related news, EVP Dan S. Johnston sold 6,250 shares of the company’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $71.71, for a total value of $448,187.50. Following the sale, the executive vice president now directly owns 27,826 shares of the company’s stock, valued at $1,995,402.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Scott Peter Seidelmann sold 1,300 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $75.17, for a total transaction of $97,721.00. Following the completion of the sale, the executive vice president now directly owns 26,333 shares in the company, valued at $1,979,451.61. The disclosure for this sale can be found here. Insiders sold 44,015 shares of company stock worth $3,368,454 over the last ninety days. 2.77% of the stock is currently owned by corporate insiders.
Several large investors have recently modified their holdings of OMCL. Whittier Trust Co. acquired a new stake in shares of Omnicell during the second quarter worth $26,000. Tower Research Capital LLC TRC acquired a new stake in shares of Omnicell during the second quarter worth $40,000. Quest Capital Management Inc. ADV acquired a new stake in shares of Omnicell during the third quarter worth $100,000. Winslow Evans & Crocker Inc. raised its holdings in shares of Omnicell by 2,876.2% during the second quarter. Winslow Evans & Crocker Inc. now owns 1,250 shares of the company’s stock worth $108,000 after purchasing an additional 1,208 shares during the period. Finally, C M Bidwell & Associates Ltd. raised its holdings in shares of Omnicell by 164.4% during the second quarter. C M Bidwell & Associates Ltd. now owns 1,375 shares of the company’s stock worth $118,000 after purchasing an additional 855 shares during the period. 98.63% of the stock is currently owned by institutional investors.
About Omnicell (NASDAQ:OMCL)
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Featured Story: Are sell-side analysts objective?
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.